Corcept Therapeutics ($CORT): Lifyorli’s launch changes the scale of the story

Corcept is now a two-product commercial company with a late-2026 regulatory binary

Corcept Therapeutics develops medicines that modulate cortisol activity through the glucocorticoid receptor. For more than a decade, the company’s commercial identity was dominated by Korlym, a mifepristone product used in a defined population of adults with endogenous Cushing’s syndrome and hyperglycemia. That product created a profitable specialty franchise and funded a broad pipeline of selective cortisol modulators.

The profile changed on March 25, 2026, when the FDA approved Lifyorli, the brand name for relacorilant, with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior systemic regimens, including at least one bevacizumab-containing regimen. The approval gave Corcept a second marketed product and validated its oncology thesis at the same time relacorilant’s separate Cushing’s application was recovering from a December 2025 Complete Response Letter.

Q2 is the first quarter in which investors can see the new model in reported numbers. Lifyorli’s $47.6 million contribution represented 18.6% of total product revenue despite being available for only its first quarter. More than 1,300 patients had started therapy and more than 1,000 physicians had prescribed the product to at least one patient. Management said demand accelerated each month and more than 70% of combined Medicare, Medicaid and commercial lives had formal coverage policies by the earnings call.

The endocrine side was also stronger. Korlym and authorized-generic revenue increased 7.3% year over year to $208.6 million, and management described record new prescriptions, first-time prescribers and patients receiving therapy. Crucially, it said the improvement was not primarily a temporary catch-up from the specialty-pharmacy transition: management characterized the transition as behind the company and attributed growth to existing patients plus record new enrollments.

Lifyorli changes the growth mix, but Korlym still funds the platform

What the Lifyorli label, ASCO data and treatment landscape mean in practice

ROSELLA was a multicenter, open-label study in 381 patients with recurrent platinum-resistant ovarian, fallopian-tube or primary-peritoneal cancer. Prior bevacizumab was required, patients could have received one to three prior systemic regimens, and the trial excluded patients who needed chronic or frequent glucocorticoids. That last point is clinically important because relacorilant antagonizes the glucocorticoid receptor and can interfere with corticosteroid treatment.

The label’s risk framework should remain visible alongside the survival benefit. Lifyorli is contraindicated in patients requiring systemic corticosteroids for lifesaving medical conditions. Warnings and precautions address neutropenia and serious infections, adrenal insufficiency, exacerbation of conditions treated with corticosteroids and embryo-fetal toxicity. Common adverse reactions and laboratory abnormalities include decreased hemoglobin and neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash and decreased appetite. Commercial adoption therefore depends not only on efficacy, but also on patient selection, supportive care, dose management and coordination when corticosteroids might otherwise be used.

ASCO 2026 answered a specific taxane-rechallenge question

The ASCO update did not change the approved label; it supplied subgroup context around ROSELLA. Corcept reported that the overall-survival benefit was observed across prespecified subgroups, including patients with recent taxane exposure. The company highlighted a hazard ratio of 0.67 in patients whose most recent regimen contained a taxane and 0.60 in patients with a taxane-free interval of six months or less.

This matters because platinum-resistant ovarian cancer is heterogeneous and physicians may hesitate to reuse a taxane-based regimen in patients recently exposed to a taxane. Consistency in those subgroups supports the clinical discussion, but subgroup estimates are less robust than the trial’s overall primary analysis and should not be interpreted as separate powered trials.

Competition is indication-specific, not one simple peer list

In Cushing’s syndrome, Corcept competes with surgery and radiation as well as therapies that reduce cortisol synthesis or action. The relevant treatment landscape includes products such as Signifor, Isturisa and Recorlev, plus ketoconazole and metyrapone in certain clinical contexts. Relacorilant’s proposed differentiation is selective glucocorticoid-receptor antagonism without progesterone-receptor binding and without some toxicities associated with existing therapies. That differentiation still requires the FDA to accept the submitted benefit-risk case.

In platinum-resistant ovarian cancer, the competitive set depends on biomarker status, prior therapy, treatment line, toxicity, access and guideline positioning. Lifyorli’s no-biomarker requirement broadens the eligible discussion, while the need to combine with nab-paclitaxel and manage corticosteroid-related considerations can limit convenience. The correct commercial question is not whether Lifyorli replaces every alternative; it is how often oncologists choose it within the defined label and how early in the platinum-resistant sequence they use it.

Multiple shots on goal, but the risk level is not equal

Why ALS remains optionality rather than a proven pillar

In DAZALS, 300 mg dazucorilant was associated in exploratory analyses with an 84% reduction in the risk of death at one year and an 87% reduction into year two. Those figures are attention-grabbing, but the randomized Phase 2 study did not meet its primary functional endpoint, ALSFRS-R. Non-serious gastrointestinal distress caused most discontinuations, which is why Corcept is running a dose-titration study before designing the planned pivotal trial.

The correct investor treatment is neither to ignore the signal nor to capitalize it as if it were confirmatory Phase 3 evidence. A credible pivotal design, regulatory alignment, tolerability improvements and replication of survival benefit are all required.

Strong liquidity does not eliminate equity-compensation dilution

Corcept reported 107.9 million common shares on its June 30 equity statement and 108.1 million shares outstanding on July 22. The comparable year-end 2025 balance was approximately 106.0 million shares. The increase reflects incentive-plan issuances and equity compensation rather than a financing transaction.

For Q2 EPS, the basic weighted-average share count was 105.4 million and the diluted count was 118.4 million. That spread should not be read as 13 million shares that will necessarily issue immediately, but it shows that options, restricted awards and participating securities can meaningfully affect per-share economics when profitable. First-half stock-based compensation was $53.1 million when capitalized amounts are included.

Corcept’s board authorized a $200 million repurchase program in January 2024. As of June 30, 2026, $11.4 million remained available; the company made no open-market repurchases under the program in the first half of 2026. A strong balance sheet therefore provides flexibility, but the current authorization is nearly exhausted and the share count has continued to rise through compensation.

The earnings-call questions focused on sustainability, not the headline beat

The Q&A was short and management provided limited quantitative detail beyond starts, prescribers and rough channel mechanics. The clean read is positive, but the company did not disclose average realized revenue per Lifyorli patient, active patients at quarter-end, discontinuation rates, average treatment duration or separate full-year revenue guidance by product.

The two honest versions of the CORT thesis

Falsifiers and monitoring rules

The narrative has shifted from recovery trade to execution leader

Before Q2, the dominant debates were whether Lifyorli could overcome launch friction, whether Korlym weakness was temporary and whether Corcept’s Q1 loss signaled an uncontrolled spending cycle. The print answered all three questions favorably for one quarter. That explains the unusually strong first-session reaction.

Retail discussion on X, Stocktwits and message boards is likely to focus on momentum, the December PDUFA and management’s multibillion-dollar ambitions. Those discussions can amplify volatility but are not evidence. The more durable indicators are product-level revenue, patient initiation, repeat prescribing, specialty-pharmacy execution, average price, operating cash flow and formal regulatory documents.

No post-Q2 analyst target changes are included in this update because no complete set of same-day actions was verified from primary or major-wire sources by the July 31 publication cutoff. Pre-print consensus figures vary by provider and methodology; the article therefore uses the company’s reported results and official guidance as the factual base.